TNFR2 antagonism has been widely accepted as a strategy to eliminate tumor-residing Tregs and activate Teff expansion, making it a potentially attractive combination therapy.4,5 Additionally, TNFR2 has been reported to be highly expressed in some tumor cells, suggesting that targeting TNFR2 might also directly kill TNFR2-expressing tumor cells.4,5 However, the detailed role of TNFR2 in PDAC cells remains to be fully investigated. This evidence concerns the gene TNFRSF1B and neoplasm.